X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-07-09 | BOLD | Boundless Bio, Inc. | Tang Kevin | 10% | P - Purchase | $2.42 | +91,585 | 2,790,103 | +3% | +$222,070 | |||||
| M | 2026-07-09 | RCUS | Arcus Biosciences, Inc. | Jaen Juan C. | Pres | S - Sale | $29.63 | -68,569 | 1,200,531 | -5% | -$2,031,919 | |||||
| D | 2026-07-09 | PTCT | Ptc Therapeutics, Inc. | Smith Mary L. | Dir | S - Sale+OE | $90.00 | -15,834 | 21,813 | -42% | -$1,425,060 | |||||
| D | 2026-07-09 | PTCT | Ptc Therapeutics, Inc. | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | S - Sale+OE | $90.25 | -2,464 | 63,198 | -4% | -$222,376 | |||||
| D | 2026-07-13 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Finance | S - Sale+OE | $84.63 | -9,999 | 15,312 | -40% | -$846,180 | |||||
| D | 2026-07-09 | DNTH | Dianthus Therapeutics, Inc. /De/ | Savitz Ryan | EVP, CFO, CBO | S - Sale+OE | $101.03 | -31,249 | 0 | -100% | -$3,157,151 | |||||
| D | 2026-07-09 | BBIO | Bridgebio Pharma, Inc. | Ellis Andrea | Dir | S - Sale+OE | $84.00 | -17,167 | 22,579 | -43% | -$1,442,028 | |||||
| D | 2026-07-09 | BBIO | Bridgebio Pharma, Inc. | Cook Jennifer E. | Dir | S - Sale+OE | $88.54 | -148,589 | 8,383 | -95% | -$13,156,008 | |||||
| D | 2026-07-10 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $544.60 | -9,500 | 668,728 | -1% | -$5,173,660 | |||||
2026-07-10 | INDV | Indivior Pharmaceuticals, Inc. | Heidbreder Christian | Chief Scientific Officer | S - Sale | $41.14 | -18,586 | 209,337 | -8% | -$764,628 | ||||||
| M | 2026-07-09 | MLTX | Moonlake Immunotherapeutics | Santos Da Silva Jorge | CEO | S - Sale | $20.02 | -102,225 | 2,774,893 | -4% | -$2,046,205 | |||||
| D | 2026-07-10 | RDHL | Redhill Biopharma Ltd. | Raday Gilead | COO | S - Sale+OE | $0.00 | -14,130,000 | 218,780,000 | -6% | -$1,413 | |||||
| M | 2026-07-09 | AMLX | Amylyx Pharmaceuticals, Inc. | Mazzariello Gina | GC | S - Sale | $17.96 | -30,000 | 179,090 | -14% | -$538,868 | |||||
| M | 2026-07-09 | SHPH | Shuttle Pharmaceuticals Holdings, Inc. | Hrt Financial LP | 10% | P - Purchase | $3.36 | +8,997 | 61,271 | +17% | +$30,212 | |||||
| M | 2026-07-09 | ADIL | Adial Pharmaceuticals, Inc. | Coastlands Capital LP | 10% | P - Purchase | $2.78 | +11,753 | 385,075 | +3% | +$32,638 | |||||
2026-07-10 | ANIX | Anixa Biosciences Inc | Kumar Amit | CEO | P - Purchase | $3.04 | +5,000 | 635,812 | +1% | +$15,200 | ||||||
2026-07-09 | PRQR | Proqr Therapeutics N.V. | De Boer Daniel Anton | CEO | P - Purchase | $1.74 | +150,000 | 300,000 | +100% | +$261,000 | ||||||
2026-07-08 | EVMN | Evommune, Inc. | Carver Kyle | CFO | P - Purchase | $13.26 | +1,000 | 60,335 | +2% | +$13,260 | ||||||
| D | 2026-07-09 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $30.30 | -2,171 | 57,733 | -4% | -$65,781 | |||||
2026-07-08 | ANTX | An2 Therapeutics, Inc. | Eizen Joshua M | See Remarks | S - Sale | $4.17 | -5,945 | 206,554 | -3% | -$24,803 | ||||||
| DM | 2026-07-08 | CTNM | Contineum Therapeutics, Inc. | Lorrain Daniel S. | Chief Scientific Officer | S - Sale+OE | $16.00 | -1,040 | 145,312 | -1% | -$16,640 | |||||
| D | 2026-07-08 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale+OE | $302.46 | -664 | 338,884 | 0% | -$200,833 | |||||
| M | 2026-07-08 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $73.80 | +529 | 507,241 | 0% | +$39,042 | |||||
2026-07-09 | NUVL | Nuvalent, Inc. | Pelish Henry E. | Chief Scientific Officer | S - Sale | $123.81 | -2,111 | 63,493 | -3% | -$261,363 | ||||||
| DM | 2026-07-08 | BCAX | Bicara Therapeutics Inc. | Cohlhepp Ryan | Pres, COO | S - Sale+OE | $28.98 | -28,750 | 181,641 | -14% | -$833,129 | |||||
| D | 2026-07-08 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | S - Sale+OE | $28.85 | -28,000 | 129,855 | -18% | -$807,672 | |||||
| D | 2026-07-09 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $117.40 | -10,699 | 492,982 | -2% | -$1,256,084 | |||||
| D | 2026-07-10 | UTHR | United Therapeutics Corp | Malcolm Jan | Dir | S - Sale+OE | $550.59 | -325 | 450 | -42% | -$178,942 | |||||
2026-07-09 | URGN | Urogen Pharma Ltd. | Schoenberg Mark | Chief Medical Officer | S - Sale | $40.00 | -10,000 | 119,763 | -8% | -$400,000 | ||||||
| D | 2026-07-08 | AKTS | Aktis Oncology, Inc. | Ron-Bigger Shulamit | COO | S - Sale+OE | $27.75 | -50,000 | 0 | -100% | -$1,387,558 | |||||
| D | 2026-07-08 | AKTS | Aktis Oncology, Inc. | Czibere Akos | Chief Medical Officer | S - Sale+OE | $27.77 | -50,000 | 0 | -100% | -$1,388,701 | |||||
| D | 2026-07-09 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $551.13 | -9,500 | 668,728 | -1% | -$5,235,756 | |||||
| D | 2026-07-07 | IRON | Disc Medicine, Inc. | Yu Jonathan Yen-Wen | COO | S - Sale+OE | $82.50 | -100 | 54,324 | 0% | -$8,250 | |||||
| D | 2026-07-07 | IONS | Ionis Pharmaceuticals Inc | Bennett C Frank | EVP, Chief Scientific Officer | S - Sale+OE | $84.95 | -20,536 | 75,018 | -21% | -$1,744,623 | |||||
2026-07-09 | ABEO | Abeona Therapeutics Inc. | Vazzano Joseph Walter | CFO | S - Sale | $6.96 | -24,880 | 493,557 | -5% | -$173,257 | ||||||
2026-07-09 | ABEO | Abeona Therapeutics Inc. | Seshadri Vishwas | CEO | S - Sale | $6.96 | -67,971 | 1,306,108 | -5% | -$473,330 | ||||||
2026-07-09 | ABEO | Abeona Therapeutics Inc. | O'Malley Brendan M. | SVP, GC | S - Sale | $6.96 | -12,050 | 427,953 | -3% | -$83,913 | ||||||
2026-07-09 | ABEO | Abeona Therapeutics Inc. | Vasanthavada Madhav | Chief Commercial Officer | S - Sale | $6.96 | -12,606 | 290,623 | -4% | -$87,784 | ||||||
| D | 2026-07-07 | IONS | Ionis Pharmaceuticals Inc | Diaz Allene M. | Dir | S - Sale+OE | $85.42 | -10,111 | 3,811 | -73% | -$863,637 | |||||
2026-07-07 | IONS | Ionis Pharmaceuticals Inc | Kordasiewicz Holly B. | EVP, Chief Development Officer | S - Sale | $84.30 | -362 | 22,096 | -2% | -$30,517 | ||||||
| M | 2026-07-07 | SHPH | Shuttle Pharmaceuticals Holdings, Inc. | Hrt Financial LP | 10% | S - Sale | $3.45 | -29,111 | 52,274 | -36% | -$100,461 | |||||
| D | 2026-07-07 | IMNM | Immunome Inc. | Horn Kinney | CHIEF BUSINESS OFFICER | S - Sale+OE | $25.00 | -1,092 | 0 | -100% | -$27,300 | |||||
| D | 2026-07-07 | ATAI | Ataibeckley Inc. | Hershberg Robert | Dir | S - Sale+OE | $4.96 | -100,000 | 100,000 | -50% | -$496,000 | |||||
| D | 2026-07-07 | IDYA | Ideaya Biosciences, Inc. | Ruiz Briseno Andres | Chief Accounting Officer | S - Sale+OE | $40.01 | -9,550 | 26,466 | -27% | -$382,131 | |||||
| D | 2026-07-08 | SNDX | Syndax Pharmaceuticals Inc | Metzger Michael A | CEO | S - Sale+OE | $24.24 | -32,375 | 484,843 | -6% | -$784,776 | |||||
2026-07-07 | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Dir | S - Sale | $44.86 | -85,918 | 2,469,959 | -3% | -$3,854,281 | ||||||
2026-07-07 | VERA | Vera Therapeutics, Inc. | Fordyce Marshall | Pres, CEO | S - Sale | $42.30 | -46,250 | 374,024 | -11% | -$1,956,187 | ||||||
2026-07-07 | SION | Sionna Therapeutics, Inc. | Orbimed Advisors LLC | Dir | S - Sale | $44.86 | -85,918 | 2,469,959 | -3% | -$3,854,281 | ||||||
2026-07-07 | IRWD | Ironwood Pharmaceuticals Inc | Silver Ronald | PFO, PAO | S - Sale | $4.52 | -127,890 | 313,680 | -29% | -$578,063 | ||||||
| D | 2026-07-08 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $553.17 | -9,500 | 668,728 | -1% | -$5,255,111 | |||||
2026-07-07 | SER | Serina Therapeutics, Inc. | Brannan Stephen K. | Dir | P - Purchase | $2.03 | +1,000 | 1,000 | New | +$2,030 | ||||||
2026-07-06 | PBYI | Puma Biotechnology, Inc. | Auerbach Alan H | Pres, CEO, 10% | S - Sale | $8.26 | -44,058 | 7,261,671 | -1% | -$364,051 | ||||||
2026-07-06 | PBYI | Puma Biotechnology, Inc. | Hunt Douglas M | See Remarks | S - Sale | $8.26 | -8,460 | 196,841 | -4% | -$69,905 | ||||||
2026-07-06 | PBYI | Puma Biotechnology, Inc. | Nougues Maximo F | CFO | S - Sale | $8.26 | -9,386 | 230,637 | -4% | -$77,557 | ||||||
| M | 2026-07-06 | BOLD | Boundless Bio, Inc. | Tang Kevin | 10% | P - Purchase | $2.48 | +57,210 | 2,698,518 | +2% | +$141,865 | |||||
2026-07-07 | EVMN | Evommune, Inc. | Kirsch Arthur S | Dir | P - Purchase | $13.30 | +10,000 | 10,000 | New | +$133,000 | ||||||
| D | 2026-07-07 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale+OE | $93.13 | -20,000 | 3,985 | -83% | -$1,862,530 | |||||
| D | 2026-07-08 | CTNM | Contineum Therapeutics, Inc. | Stengone Carmine N. | CEO, Pres | S - Sale+OE | $16.00 | -2,500 | 17,217 | -13% | -$40,000 | |||||
| M | 2026-07-06 | DYN | Dyne Therapeutics, Inc. | Rhodes Jason P | Dir | S - Sale | $22.97 | -777,451 | 2,962 | -100% | -$17,858,492 | |||||
| M | 2026-07-06 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $0.31 | -143,199 | 0 | -100% | -$44,749 | |||||
| D | 2026-07-06 | PTCT | Ptc Therapeutics, Inc. | Boulding Mark Elliott | EVP, CLO | S - Sale+OE | $85.08 | -5,079 | 105,272 | -5% | -$432,118 | |||||
| DM | 2026-07-06 | PTCT | Ptc Therapeutics, Inc. | Almstead Neil Gregory | CHIEF TECHNICAL OPS OFFICER | S - Sale+OE | $87.52 | -46,774 | 63,198 | -43% | -$4,093,482 | |||||
2026-07-06 | ELVN | Enliven Therapeutics, Inc. | Kunkel Lori Anne | Dir | S - Sale | $50.49 | -10,000 | 41,884 | -19% | -$504,903 | ||||||
| D | 2026-07-06 | MIRM | Mirum Pharmaceuticals, Inc. | Peetz Christopher | CEO | S - Sale+OE | $122.27 | -20,000 | 381,809 | -5% | -$2,445,382 | |||||
2026-07-06 | MIRM | Mirum Pharmaceuticals, Inc. | Bjerkholt Eric | CFO | S - Sale | $122.26 | -5,000 | 42,181 | -11% | -$611,273 | ||||||
| D | 2026-07-07 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $558.87 | -9,500 | 668,728 | -1% | -$5,309,296 | |||||
| D | 2026-07-06 | ALMS | Alumis Inc. | Pangali Sanam | GC | S - Sale+OE | $28.00 | -5,000 | 11,111 | -31% | -$140,000 | |||||
2026-07-06 | ORIC | Oric Pharmaceuticals, Inc. | Heyman Richard A. | Dir | S - Sale | $12.00 | -300 | 254,572 | 0% | -$3,600 | ||||||
| D | 2026-07-06 | NUVL | Nuvalent, Inc. | Porter James Richard | Pres, CEO | S - Sale+OE | $123.72 | -30,000 | 324,879 | -8% | -$3,711,600 | |||||
| M | 2026-07-06 | LQDA | Liquidia Corp | Bloch Stephen M | Dir | S - Sale | $80.68 | -75,000 | 851,667 | -8% | -$6,051,170 | |||||
| M | 2026-07-06 | TBPH | Theravance Biopharma, Inc. | Samaha Eli | 10% | S - Sale | $17.14 | -6,964 | 9,167,489 | 0% | -$119,397 | |||||
2026-07-06 | LRMR | Larimar Therapeutics, Inc. | Hamilton Thomas Edward | Dir | P - Purchase | $3.34 | +50,000 | 874,231 | +6% | +$166,890 | ||||||
| D | 2026-07-06 | INSM | Insmed Inc | Flammer Martina M.D. | Chief Medical Officer | S - Sale+OE | $109.98 | -12,302 | 60,486 | -17% | -$1,352,932 | |||||
2026-07-07 | PRQR | Proqr Therapeutics N.V. | De Boer Daniel Anton | CEO | P - Purchase | $1.59 | +150,000 | 150,000 | New | +$238,500 | ||||||
| M | 2026-07-06 | NGNE | Neurogene Inc. | Cvijic Christine Mikail | Pres, CFO | S - Sale | $36.12 | -4,800 | 84,040 | -5% | -$173,375 | |||||
| D | 2026-07-06 | DMRA | Damora Therapeutics, Inc. | Winslow Garrett | GC | S - Sale+OE | $29.98 | -245 | 2,289 | -10% | -$7,345 | |||||
| D | 2026-07-06 | NBP | Novabridge Biosciences | Xu Cong Claire | SVP, Clinical Development | S - Sale+OE | $0.89 | -4,485 | 298,101 | -1% | -$3,992 | |||||
| M | 2026-07-06 | IMNM | Immunome Inc. | Barchas Isaac | Dir | S - Sale | $24.13 | -100,000 | 211,763 | -32% | -$2,412,522 | |||||
| D | 2026-07-02 | STTK | Shattuck Labs, Inc. | Shukla Abhinav A. | Chief Technical Officer | S - Sale+OE | $7.01 | -410 | 98,533 | 0% | -$2,874 | |||||
| M | 2026-07-02 | ETON | Eton Pharmaceuticals, Inc. | Opaleye Management Inc. | 10% | S - Sale | $37.64 | -126,685 | 2,733,315 | -4% | -$4,768,637 | |||||
| M | 2026-07-02 | KRRO | Korro Bio, Inc. | Formela Jean Francois | Dir | S - Sale | $14.02 | -110,023 | 146,305 | -43% | -$1,542,970 | |||||
| D | 2026-07-02 | IMNM | Immunome Inc. | Lechleider Robert | Chief Medical Officer | S - Sale+OE | $22.62 | -55,000 | 15,805 | -78% | -$1,244,331 | |||||
| M | 2026-07-06 | XERS | Xeris Biopharma Holdings, Inc. | Pieper Steven | See Remarks | S - Sale | $8.52 | -45,000 | 1,366,053 | -3% | -$383,176 | |||||
| D | 2026-07-07 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $86.62 | -3,500 | 153,902 | -2% | -$303,170 | |||||
| M | 2026-07-02 | BCYC | Bicycle Therapeutics Plc | Perry Jennifer Scott | COO | S - Sale | $4.29 | -1,412 | 91,052 | -2% | -$6,054 | |||||
| M | 2026-07-02 | BCYC | Bicycle Therapeutics Plc | Skynner Michael | CHIEF SCIENTIFIC OFFICER | S - Sale | $4.28 | -2,391 | 157,171 | -1% | -$10,231 | |||||
| M | 2026-07-02 | BCYC | Bicycle Therapeutics Plc | Lee Kevin | CEO | S - Sale | $4.28 | -7,642 | 603,671 | -1% | -$32,701 | |||||
| M | 2026-07-02 | BCYC | Bicycle Therapeutics Plc | Hannay Michael Charles Ferguson | CHIEF PROD, SUPPLY CHAIN OFF | S - Sale | $4.28 | -1,761 | 94,375 | -2% | -$7,530 | |||||
| M | 2026-07-02 | BCYC | Bicycle Therapeutics Plc | Thompson Travis Alvin | CFO | S - Sale | $4.27 | -923 | 64,441 | -1% | -$3,945 | |||||
2026-07-06 | IMNN | Imunon, Inc. | Eylward Susan | GC, Corp Sec | S - Sale | $1.88 | -920 | 2,896 | -24% | -$1,730 | ||||||
| D | 2026-07-02 | QURE | Uniqure N.V. | Kapusta Matthew C | CEO, MD | S - Sale+OE | $45.16 | -21,082 | 519,227 | -4% | -$952,051 | |||||
| D | 2026-07-06 | SION | Sionna Therapeutics, Inc. | Fitzpatrick Jennifer | GC | S - Sale+OE | $43.60 | -10,250 | 0 | -100% | -$446,862 | |||||
2026-07-02 | CRNX | Crinetics Pharmaceuticals, Inc. | Vivaldi Coelho Rogerio | Dir | S - Sale | $40.00 | -3,000 | 19,225 | -13% | -$120,000 | ||||||
2026-07-02 | SHPH | Shuttle Pharmaceuticals Holdings, Inc. | Hrt Financial LP | 10% | P - Purchase | $3.54 | +7,851 | 81,385 | +11% | +$27,793 | ||||||
2026-07-06 | SHPH | Shuttle Pharmaceuticals Holdings, Inc. | Hrt Financial LP | 10% | S - Sale | $3.51 | -9,022 | 81,385 | -10% | -$31,667 | ||||||
2026-07-02 | VRTX | Vertex Pharmaceuticals Inc / Ma | Tatsis Ourania | EVP, Chief Reg., Quality Offic | S - Sale | $524.99 | -1,500 | 45,321 | -3% | -$787,485 | ||||||
2026-07-02 | VRTX | Vertex Pharmaceuticals Inc / Ma | McKechnie Duncan | EVP, Chief Commercial Officer | S - Sale | $519.00 | -1,541 | 11,001 | -12% | -$799,779 | ||||||
2026-07-02 | REGN | Regeneron Pharmaceuticals, Inc. | Ryan Arthur F | Dir | S - Sale | $650.15 | -200 | 17,303 | -1% | -$130,030 | ||||||
| D | 2026-07-06 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $548.96 | -9,500 | 668,728 | -1% | -$5,215,133 | |||||
| D | 2026-07-02 | ANIP | Ani Pharmaceuticals Inc | Carey Stephen P. | SVP, CFO | S - Sale+OE | $86.00 | -3,313 | 177,543 | -2% | -$284,918 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |